Tango Biosciences scientists, in collaboration with colleagues from B2S Life Sciences, LifeTein, and Euprotein, publish a scientific report on generating recombinant affinity reagents (monobodies) to the receptor binding domain (RBD) of the SARS-CoV-2 virus, which is responsible for the COVID-19 pandemic. Soluble forms of the monobodies bound to several different preparations of the RBD and the S1 spike subunit, with affinities ranging from 3 to 14 nM as measured by bio-layer interferometry. All four monobodies successfully bound the RBD after overexpression in Chinese hamster ovary (CHO) cells as fusions to the Fc domain of human IgG1. The paper was published February 5, 2021 in the peer-reviewed journal, New Biotechnology, and can be found below.
Tango Biosciences publishes work on SARS-CoV-2 virus
More News and Events
-
Tango Biosciences Celebrates 10 Years of Discovery
This year Tango Biosciences celebrates their ten-year anniversary, a milestone that resonates with scientific innovation and a sustained commitment to solving complex challenges in drug discovery and diagnostics. Visionary founders Dr. Brian Kay and Michael Scholle recently sat down to take a deep dive into the company’s incredible journey. They revealed an origin story that perfectly […]
-
Event
SLAS 2026
Visit Tango Biosciences at the 2026 SLAS International Conference & Exhibition! February 7-11, 2026 | Boston, MA Booth #1435 Plus, mark your calendar to join our Solutions Spotlight and poster presentations: Solutions Spotlight Presentation: Phage display in action: accelerating peptide, antibody, and molecular glue discovery through affinity, selectivity, and speed Wednesday, February 11 | 11:00am […]
-
NIH Awards New SBIR Grant
The National Institutes of Health (NIH) awarded a phase I SBIR grant to Tango Biosciences in July 2025. This award will support the application of Tango Biosciences’ proprietary Avidimer platform for the development of protein tools that enhance the discovery of proximity inducing modalities such as molecular glues. The Avidimers developed in this program will generate proof-of-concept […]